<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587884</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2015-01-024</org_study_id>
    <nct_id>NCT02587884</nct_id>
  </id_info>
  <brief_title>Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH</brief_title>
  <official_title>Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on
      the prognosis of patients with microvascular invasion presence(MVI) and overexpression of
      Aspartate-β-hydroxylase(ASPH).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will treated with TACE after resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will treated without TACE after resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Patients will treated by TACE in 4 or 8 weeks after operation.</description>
    <arm_group_label>Group TACE</arm_group_label>
    <other_name>Transhepatic Arterial Chemotherapy And Embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Via clinical diagnosis and confirm it is primary liver cancer

          2. Pathological evidence of HCC

          3. Confirm presence of MVI and over-expression of ASPH after opreation

          4. Within Milan criteria

          5. Estimate tumor can gain treatment of curing operation

          6. No evidence for extrahepatic metestasis

          7. liver function ：Child-Pugh A/B

        Exclusion Criteria:

          1. Reject to attend

          2. Impossible to come to our hospital for physical examination regularly

          3. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction

          4. Female with pregnancy or during the lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Feng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Kui, MD</last_name>
    <phone>86-021-81875242</phone>
    <email>wangkuiykl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern hepatobilliary surgery hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Shen, MD</last_name>
      <phone>0086-021-25070805</phone>
      <email>shenfengdfgd@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yong Xia, Doctor</last_name>
      <phone>86-021-81875495</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospital Affiliation: Eastern Hepatobiliary Surgery Hospital</investigator_title>
  </responsible_party>
  <keyword>Recurrence</keyword>
  <keyword>Microvascular Invasion</keyword>
  <keyword>Aspartate beta-hydroxylase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

